ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Recommendation of “Moderate Buy” by Brokerages

ProQR Therapeutics N.V. (NASDAQ:PRQR) has received a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $7.1429.

Several analysts recently issued reports on the stock. Chardan Capital restated a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a report on Friday, August 8th. Evercore ISI restated an “outperform” rating on shares of ProQR Therapeutics in a report on Friday, July 11th. Zacks Research lowered shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Wednesday, October 8th.

ProQR Therapeutics Stock Up 1.1%

Shares of ProQR Therapeutics stock opened at $2.75 on Friday. The firm has a market capitalization of $289.33 million, a P/E ratio of -5.98 and a beta of 0.23. ProQR Therapeutics has a 52 week low of $1.07 and a 52 week high of $4.21. The company has a 50 day moving average price of $2.39 and a 200 day moving average price of $2.07.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.06). The company had revenue of $4.33 million during the quarter, compared to analysts’ expectations of $5.01 million. ProQR Therapeutics had a negative net margin of 238.52% and a negative return on equity of 61.25%. As a group, research analysts anticipate that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

Institutional Trading of ProQR Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Affinity Asset Advisors LLC increased its stake in ProQR Therapeutics by 16.3% during the first quarter. Affinity Asset Advisors LLC now owns 3,284,512 shares of the biopharmaceutical company’s stock worth $4,368,000 after purchasing an additional 459,512 shares during the period. OneDigital Investment Advisors LLC increased its stake in ProQR Therapeutics by 45.5% during the first quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 12,500 shares during the period. Monaco Asset Management SAM increased its stake in ProQR Therapeutics by 59.1% during the first quarter. Monaco Asset Management SAM now owns 471,908 shares of the biopharmaceutical company’s stock worth $628,000 after purchasing an additional 175,290 shares during the period. Vontobel Holding Ltd. purchased a new stake in ProQR Therapeutics during the first quarter worth about $48,000. Finally, Aberdeen Group plc purchased a new stake in ProQR Therapeutics during the first quarter worth about $2,461,000. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).